Table II.
TRAIL-specific lncRNAs involved in breast cancer and their targets.
| Author, year | lncRNA | Expression | Target | Mechanism | (Refs.) |
|---|---|---|---|---|---|
| Si et al, 2016 | H19 | High | BIK | Blocking promoter region | (121) |
| Hung et al, 2011, Zhang et al, 2014 | PANDA | High | APAF1, BIK, FAS | Interact with NF-YA | (127,128) |
| He et al, 2015 | GAS-5 | Low | BIK | Expression activation via epigenetic modification | (133) |
| Zhang et al, 2019 | CASC-2 | Low | Smad-2 | Direct inhibition | (137) |
| Si et al, 2016 | HOXA-AS2 | High | TGFBR2 | Expression facilitation via directly inhibiting miR-520c-3p | (121) |
BIK, Bcl2 interacting killer; APAF, apoptotic protease-activating factor-1; CASC-2, cancer susceptibility 2; FAS, apoptosis antigen 1; GAS, growth arrest-specific 5; HOXA-AS2, HOXA cluster antisense 2 RNA; NF-YA, nuclear transcription factor Y; PANDA, p21-associated ncRNA DNA damage activated; TGFBR2, tumor growth factor β receptor 2.